Latest Racing News

PYC Therapeutics has secured Safety Review Committee approval to increase dosing in its clinical trial for a novel treatment targeting Autosomal Dominant Optic Atrophy, a rare blinding genetic disease. This milestone marks a significant step forward in the development of PYC-001, a first-in-class RNA therapy.

Radiopharm Theranostics has secured FDA Fast Track designation for RAD101, a novel imaging agent aimed at improving diagnosis of recurrent brain metastases. The move could speed development and regulatory review as the company advances its Phase 2 clinical trial.

Dateline Resources secures high-level U.S. government endorsement for its Colosseum Rare Earths Project, highlighting its strategic role in domestic critical minerals supply. The project’s significant gold resources and rare earth potential position it as a key player in America’s mineral independence efforts.

Syntara Limited’s lead drug candidate SNT-5505 has secured FDA Fast Track designation, expediting its development for treating myelofibrosis, a rare and serious blood cancer with limited therapies.

BetMakers Technology Group launches a $13.5 million equity raise to fund the acquisition of Las Vegas Dissemination Company and strengthen its financial position amid improving operational metrics.

Chimeric Therapeutics has secured FDA Fast Track designation for its CHM CDH17 CAR-T therapy targeting gastroenteropancreatic neuroendocrine tumours, accelerating its path toward regulatory approval and patient access.

BetMakers Technology Group reports solid Q3 FY25 financial gains alongside a strategic binding agreement to acquire Nevada’s LVDC, expanding its global racing technology footprint.

BetMakers Technology Group is poised to expand its North American footprint by acquiring LVDC, Nevada’s exclusive pari-mutuel wagering provider, targeting an initial A$4 million in annual revenue.

PointsBet has secured a significantly improved acquisition proposal from MIXI, lifting the cash offer by 13.2% to $1.20 per share and postponing the shareholder vote to June 25. The move intensifies the takeover battle amid ongoing regulatory approvals and a rival bid from Betr Entertainment.

MTM Critical Metals has achieved a breakthrough in recovering high-grade antimony from U.S.-sourced electronic waste, surpassing traditional mine grades and supporting U.S. efforts to secure critical metal supplies amid global supply disruptions.

Amplia Therapeutics reports strong progress in its pancreatic cancer drug development, completing the ACCENT trial recruitment ahead of schedule and initiating a new US trial, while managing a $6.57 million loss for FY25.

Clarity Pharmaceuticals has successfully imaged the first patient in its pivotal Phase III AMPLIFY trial for Cu-SAR-bisPSMA, a next-generation diagnostic agent targeting recurrent prostate cancer. This milestone sets the stage for potential FDA approval and broader clinical adoption.